Tirzepatide: A Double Agonist for Various People Living with Type 2 Diabetes.
Felice StrolloGiuseppina GuarinoErsilia SattaSandro GentilePublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Tirzepatide is the first ever once-weekly, injectable gastric inhibitory peptide/glucagon-like peptide 1 (GIP/GLP-1) dual agonist approved by the European Medicines Agency for type 2 diabetes. The efficacy and safety of tirzepatide have been evaluated in five global, randomized, double-blind or open-label, phase 3 studies which enrolled over 7000 people living with type 2 diabetes, across various stages of disease and with different characteristics at baseline. In this short commentary we report the salient data of the most recent trials on tirzepatide and GLP-1 receptor agonists from a clinical point of view, with the aim of highlighting similarities and mutual differences.
Keyphrases
- open label
- double blind
- phase iii
- placebo controlled
- phase ii
- type diabetes
- clinical trial
- study protocol
- phase ii study
- drug administration
- electronic health record
- cardiovascular disease
- big data
- randomized controlled trial
- insulin resistance
- glycemic control
- metabolic syndrome
- squamous cell carcinoma
- case control
- artificial intelligence